Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCd induction/consolidation followed by pomalidomide + dexamethasone versus pomalidomide maintenance in relapsed multiple myeloma
2013-003265-34Phase 2Completed
- Sponsor
- HOVON
- Start
- Jan 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pomalidomide, carfilzomib and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by HOVON. Primary endpoint: Progression-free survival. Started Jan 2015; status: completed.
02
Drugs
pomalidomidecarfilzomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2013-003265-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003265-34.